Pharmacopsychiatry 2010; 43(2): 58-65
DOI: 10.1055/s-0029-1239540
Original Paper

© Georg Thieme Verlag KG Stuttgart · New York

Serum Concentrations, Therapeutic Response and Side Effects in Children and Adolescents with Impulsive-Aggressive Symptoms during Risperidone Therapy

K. Klampfl1 , R. Taurines1 , A. Preuss1 , R. Burger4 , S. Rothenhöfer2 , Ch. Wewetzer2 , B. Pfuhlmann4 , J. Fegert3 , M. Gerlach1 , 4 , C. Mehler-Wex3
  • 1Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany
  • 2Clinics of City Cologne GmbH, Child and Adolescent Psychiatry and Psychotherapy, Cologne, Germany
  • 3Department of Child and Adolescent Psychiatry and Psychotherapy, University of Ulm, Ulm Germany
  • 4Laboratory for Therapeutic Drug Monitoring, Clinics for Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany
Further Information

Publication History

received 29.05.2009 revised 25.07.2009

accepted 06.08.2009

Publication Date:
10 December 2009 (online)

Abstract

Introduction: The aim of this prospective naturalistic study was to examine for the first time the relationship between dosage, serum concentration and clinical outcome in children and adolescents with impulsive-aggressive symptoms during risperidone therapy.

Methods: Steady state trough serum concentrations of risperidone and 9-hydroxyrisperidone (the active moiety) were measured in 103 subjects. The therapeutic effect was assessed by the clinical global impression improvement subscale and side effects by the Udvalg for Kliniske Undersogelser-side effect rating scale.

Results: We found a linear relationship between the risperidone dose and the serum concentration of the active moiety (Spearman ρ=0.53) and no correlation between the serum concentration and either the therapeutic effect or side effects. There was no effect of gender and co-medication.

Discussion: This study has the typical limitations of naturalistic studies, therefore our results should be interpreted with caution. Based on the serum concentrations at the therapeutically effective dose range (0.25–1.5 mg/day) we obtained first information on a possibly appropriate therapeutic serum range for the risperidone treatment of children and adolescents with impulsive-aggressive symptoms. Further studies with greater sample sizes are needed to validate our results and to examine the influence of genetic polymorphisms on the serum concentration of risperidone.

References

Correspondence

Dr. med. K. Klampfl

Department of Child and Adolescent Psychiatry Psychosomatics and Psychotherapy

University of Wuerzburg

Fuechsleinstraße 15

97080 Würzburg

Germany

Phone: +49/931/201 78010

Fax: +49/931/201 78040

Email: klampfl@kjp.uni-wuerzburg.de